Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Clinical Labs to Market Ikonisys Cervical Cancer Test

NEW YORK (GenomeWeb News) – Enzo Biochem's Enzo Clinical Labs division will market Ikonisys' OncoFISH cervical test, under an agreement announced today.

Enzo Clinical Labs will have exclusive marketing rights for the test in New York and New Jersey. It will offer the assay to doctors requesting advanced analysis of specimens from liquid-based Pap tests to assist them in evaluating cytologic reports. Ikonisys will conduct the evaluation of the specimen using its own CellOptics platform on the Ikoniscope Digital Microscopy System for interpreting molecular signals.

Enzo said that he assay is based on the identification of a genetic marker that has been linked with an increased likelihood for the development of cervical cancer.

In addition, the firm noted that the test already has received clearance in New York State.

"The results of Pap smears are not always conclusive," Kevin Krenitsky, president of Enzo Clinical Labs, said in a statement. "OncoFISH cervical provides an important new dimension for further evaluation, tied to chromosome related indicators, to determine the probability of progression to cervical cancer where the current results are indecisive or suspicious."

Terms of the pact were not disclosed.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.